Bright Minds Biosciences Inc. Common Stock DRUG
i
Market datapartial · fetched 2026-11-12T14:58:03.182Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T14:56:31.939445169Z
FundamentalsAlpha Vantage · unavailable
Bright Minds Biosciences Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 16.15 | 451.3% | 39.9% | |||
| 25Δ | 18.24 | 360.9% | 30.7% | |||
| 30Δ | 19.95 | 292.2% | 23.2% | |||
| 35Δ | 20.99 | 251.4% | 18.6% | |||
| 40Δ | 26.93 | 242.1% | 26.9% | 22.01 | 211.4% | 14.2% |
| 45Δ | 25.58 | 241.4% | 22.4% | 22.71 | 183.7% | 11.2% |
| 50Δ | 24.29 | 220.7% | 17.3% | 23.12 | 167.2% | 9.5% |
| 55Δ | 23.05 | 184.9% | 11.9% | 23.52 | 150.6% | 7.9% |
| 60Δ | 22.20 | 162.7% | 8.6% | 23.92 | 134.0% | 6.3% |
| 65Δ | 21.65 | 151.2% | 7.0% | 24.33 | 117.5% | 4.6% |
| 70Δ | 21.11 | 139.7% | 5.4% | 24.73 | 100.9% | 3.0% |
| 75Δ | 20.57 | 128.2% | 3.8% | |||
| 80Δ | 20.03 | 116.7% | 2.2% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.15
- IV
- 451.3%
- B/E move
- 39.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.24
- IV
- 360.9%
- B/E move
- 30.7%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.95
- IV
- 292.2%
- B/E move
- 23.2%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 20.99
- IV
- 251.4%
- B/E move
- 18.6%
40Δ
- Pseudo strike
- 26.93
- IV
- 242.1%
- B/E move
- 26.9%
- Pseudo strike
- 22.01
- IV
- 211.4%
- B/E move
- 14.2%
45Δ
- Pseudo strike
- 25.58
- IV
- 241.4%
- B/E move
- 22.4%
- Pseudo strike
- 22.71
- IV
- 183.7%
- B/E move
- 11.2%
50Δ
- Pseudo strike
- 24.29
- IV
- 220.7%
- B/E move
- 17.3%
- Pseudo strike
- 23.12
- IV
- 167.2%
- B/E move
- 9.5%
55Δ
- Pseudo strike
- 23.05
- IV
- 184.9%
- B/E move
- 11.9%
- Pseudo strike
- 23.52
- IV
- 150.6%
- B/E move
- 7.9%
60Δ
- Pseudo strike
- 22.20
- IV
- 162.7%
- B/E move
- 8.6%
- Pseudo strike
- 23.92
- IV
- 134.0%
- B/E move
- 6.3%
65Δ
- Pseudo strike
- 21.65
- IV
- 151.2%
- B/E move
- 7.0%
- Pseudo strike
- 24.33
- IV
- 117.5%
- B/E move
- 4.6%
70Δ
- Pseudo strike
- 21.11
- IV
- 139.7%
- B/E move
- 5.4%
- Pseudo strike
- 24.73
- IV
- 100.9%
- B/E move
- 3.0%
75Δ
- Pseudo strike
- 20.57
- IV
- 128.2%
- B/E move
- 3.8%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 20.03
- IV
- 116.7%
- B/E move
- 2.2%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 70.22% | |
| 68.72% | |
| 69.79% | |
| 71.90% | |
| 71.78% | |
| 71.26% | |
| 71.39% | |
| 69.84% | |
| 69.52% | |
| 73.76% |
Biotechnology
DSGN
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad,…
More →DTIL
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
More →DYN
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The…
More →EDIT
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is…
More →ELDN
Description unavailable
More →ELTX
Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. Its lead product candidate, Eli-002,…
More →